Less Ads, More Data, More Tools Register for FREE

Pin to quick picksForterra Regulatory News (FORT)

Share Price Information for Forterra (FORT)

Share Price is delayed by 15 minutes
Get Live Data
132.20    -1.60 (-1.20%)
Bid:
132.20
Ask:
132.60
Spread: 0.40 (0.303%)
Market Cap: £271.70m
FORT Live PriceLast checked at - London Stock Exchange

Intraday Forterra Share Chart

Director/PDMR Shareholding

27 Apr 2018 13:14

RNS Number : 4279M
Forterra plc
27 April 2018
 

27 April 2018

Forterra plc

PDMR Shareholdings

Forterra plc (the "Company") was notified on 26 April 2018 that on the same day Matthew Clay, Managing Director, Bespoke Products and Darren Rix, Strategy and Development Director both of whom are defined as Persons Discharging Management Responsibilities (PDMR's) exercised share options over the Company's ordinary shares of 1p each ("ordinary shares") granted under the Forterra Deferred Annual Bonus Plan.

The options were granted as nominal (1p) cost options although this sum was waived by the Company on exercise. The number of options exercised also includes a dividend equivalent in addition to the options initially granted in accordance with the rules of the scheme. On exercise, sufficient shares were immediately sold to cover tax, NI and transaction costs.

No new shares were issued in respect of these transactions with the shares being transferred to the individuals from the Forterra Employee Benefit Trust.

Name

Number of options exercised

Number of shares transferred to individual after paying tax, NI and transaction costs

Number of shares now beneficially held by individual

Matthew Clay

18,779

9,921

9,921

Darren Rix

11,768

6,217

6,217

 

 

Enquiries

 

Forterra plc:

+44 (0) 1604 707 600

Shatish Dasani (CFO)

Ben Guyatt (Company Secretary)

FTI Consulting:

+44 (0) 20 3727 1340

Richard Mountain/Nick Hasell

 

Further information relating to the Company and its group can be found at www.forterraplc.co.uk.

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Matthew Clay

2.

Reason for the notification

a)

Position/status

Managing Director Bespoke Products (PDMR)

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Forterra plc

b)

LEI

5299007SD2PDQMKM5278

4.

Details of the transaction(s):

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each

 

GB00BYYW3C20

b)

Nature of the transaction

(i) Acquisition of 18,779 shares in the Company following the vesting of an award granted under the DABP on 1 June 2016; and (ii) subsequent sale of 8,858 shares to cover PAYE/NI liabilities arising from such vesting. The remainder of the shares (9,921) are being retained

c)

Price(s) and volume(s)

Transaction

Price(s)

Volume(s)

(i) Acquisition

Nil

18,779

(ii) Sale

£3.06

8,858

d)

Aggregated information

 

Transaction

Price(s)

Volume(s)

Total

 (i) Acquisition

Nil

18,779

Nil

 (ii) Sale

£3.06

8,858

£27,105.48

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Darren Rix

2.

Reason for the notification

a)

Position/status

Strategy and Development Director (PDMR)

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Forterra plc

b)

LEI

5299007SD2PDQMKM5278

4.

Details of the transaction(s):

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each

 

GB00BYYW3C20

b)

Nature of the transaction

(i) Acquisition of 11,768 shares in the Company following the vesting of an award granted under the DABP on 1 June 2016; and (ii) subsequent sale of 5,551 shares to cover PAYE/NI liabilities arising from such vesting. The remainder of the shares (6,217) are being retained

c)

Price(s) and volume(s)

Transaction

Price(s)

Volume(s)

(i) Acquisition

Nil

11,768

(ii) Sale

£3.06

5,551

d)

Aggregated information

 

Transaction

Price(s)

Volume(s)

Total

 (i) Acquisition

Nil

11,768

Nil

 (ii) Sale

£3.06

5,551

£16,986.06

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHPGUCGCUPRGPM
Date   Source Headline
19th Jun 20264:22 pmRNSHolding(s) in Company
17th Jun 202612:17 pmRNSEmployee Benefit Trust Share Purchase
16th Jun 20267:00 amRNSTransaction in Own Shares
15th Jun 20262:39 pmRNSDirector / PCA Shareholdings
11th Jun 20262:52 pmRNSGrant under Long Term Incentive Plan
11th Jun 20267:00 amRNSDirectorate change
9th Jun 202611:53 amRNSHolding(s) in Company
9th Jun 20267:00 amRNSTransaction in Own Shares
3rd Jun 20269:45 amRNSTransaction in Own Shares
2nd Jun 202612:32 pmRNSEmployee Benefit Trust Share Purchase
2nd Jun 202612:30 pmRNSTotal Voting Rights and Capital
1st Jun 20267:00 amRNSAppointment of New Independent NED
27th May 20267:00 amRNSTransaction in Own Shares
21st May 20265:03 pmRNSHolding(s) in Company
19th May 20264:41 pmRNSAnnual General Meeting 2026 Results
19th May 20267:01 amRNSTransaction in Own Shares
19th May 20267:00 amRNSAGM Trading Update
12th May 20261:32 pmRNSTransaction in Own Shares
12th May 20267:00 amRNSAGM RESOLUTION – APPROVAL OF REMUNERATION POLICY
7th May 20261:43 pmRNSHolding(s) in Company
6th May 202610:50 amRNSTransaction in Own Shares
6th May 20269:58 amRNSTotal Voting Rights and Capital
6th May 20269:55 amRNSEmployee Benefit Trust Share Purchase
28th Apr 202610:20 amRNSHolding(s) in Company
28th Apr 202610:18 amRNSTransaction in Own Shares
21st Apr 202611:31 amRNSTransaction in Own Shares
16th Apr 20267:00 amRNSEmployee Benefit Trust Share Purchase
15th Apr 20265:40 pmRNSNotice of Annual General Meeting 2026
14th Apr 202610:00 amRNSTransaction in Own Shares
14th Apr 20267:00 amRNSAppointment of new Independent NED
9th Apr 202610:15 amRNSHolding(s) in Company
9th Apr 20267:00 amRNSDirector Declaration
8th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20262:07 pmRNSTotal Voting Rights
7th Apr 202612:47 pmRNSEmployee Benefit Trust Share Purchase
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20261:03 pmRNSDirector / PCA Shareholdings
25th Mar 202610:50 amRNSAnnual Report and Accounts 2025
24th Mar 202610:40 amRNSTransaction in Own Shares
24th Mar 20269:01 amRNSHolding(s) in Company
24th Mar 20267:00 amRNSReplacement:Grant under Deferred Annual Bonus Plan
20th Mar 20268:45 amRNSGrant under Deferred Annual Bonus Plan
17th Mar 20267:00 amRNSEmployee Benefit Trust Share Purchase
17th Mar 20267:00 amRNSEmployee Benefit Trust Share Purchase
16th Mar 202610:32 amRNSLaunch of £20m Share Buyback Programme
16th Mar 202610:32 amRNSLaunch of £20m Share Buyback Programme
11th Mar 20267:00 amRNSFull Year Results
3rd Mar 20263:27 pmRNSEmployee Benefit Trust Share Purchase
18th Feb 20262:27 pmRNSEmployee Benefit Trust Share Purchase
3rd Feb 202612:26 pmRNSEmployee Benefit Trust Share Purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.